What is the Gland Pharma Ltd share price today?

The share price of NSE:GLAND-EQ on 01 Oct 2026 (as of 15:03:36 IST) is ₹2873.9.

What is the NSE:GLAND-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:GLAND-EQ 52 week high low range shows a high of ₹3042 and a low of ₹1573.6.

What is the Gland Pharma Ltd market cap?

As on 01 Oct 2026, Gland Pharma Ltd market cap is ₹479192000000.

What is the shareholding pattern of Gland Pharma Ltd Stock?

The shareholding pattern of Gland Pharma Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 51.77% Foreign Institutional Investors (FII): 8.74% Domestic Institutional Investors (DII): 2.21% Mutual Funds: 28.23% Retail & Others: 9.05% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Gland Pharma Ltd?

The Price-to-Earnings (PE) ratio of Gland Pharma Ltd is 42.4517, and the Price-to-Book (PB) ratio is 2.7117, as on 01 Oct 2026.

Gland Pharma Share Price

3158.90+92.30 (+3.01%)

+63.77% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+3.01%

1 Week

+2.75%

1 Month

+9.90%

3 Month

+24.12%

6 Month

+68.87%

YTD

+83.44%

1 Year

+63.77%

5 Year

-14.59%

10 Year

Max

+84.73%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

3035.00

2769.80

2557.00

1813.00

1573.60

High

3168.30

3171.00

About

Gland Pharma Limited is focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. It has established a portfolio of injectable products across various Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

LAURUSLABSNSE

ZYDUSLIFENSE

DRREDDYNSE

CIPLANSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

GLANDNSE

LTP

1W Low

1W High

Market cap (₹)

1772.5+11.5 (0.65%)

1722

1855

4,24,202Cr

9953+289 (2.99%)

9621.50

10024.50

2,64,141Cr

4623.1+43.1 (0.94%)

4532

4675

1,74,402Cr

2297+53 (2.36%)

2206.10

2441.90

1,26,811Cr

1241.6+57.2 (4.83%)

1182

1254.20

1,23,685Cr

1355.9+10.9 (0.81%)

1336.70

1364.90

1,11,868Cr

1383.7+25.7 (1.89%)

1357

1392

1,11,650Cr

2470.7+1.4 (0.06%)

2457.90

2528

1,02,196Cr

1684+24.1 (1.45%)

1647.20

1694.60

96,951Cr

2010.6+20.7 (1.04%)

1974

2033.80

91,301Cr

3140.9+66.4 (2.16%)

3035

3145.90

50,598Cr

Gland Pharma Share Price

3158.90+92.30 (+3.01%)

+63.77% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years13%

3 years21%

Last year14%

Compounded Profit Growth

10 years-

5 years1%

3 years10%

Last year47%

Stock Price CAGR

10 years-

5 years-4%

3 years27%

1 year59%

Return on Equity

10 years14%

5 years11%

3 years9%

Last year11%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	13%	21%	14%
-	1%	10%	47%
-	-4%	27%	59%
14%	11%	9%	11%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

LAURUSLABS

ZYDUSLIFE

DRREDDY

CIPLA

MANKIND

AUROPHARMA

LUPIN

GLAND

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,772.5	₹424202 Cr	38.68	8.29	58.23	₹11479 Cr
9,953	₹264141 Cr	90.3	34.04	128.41	₹2568 Cr
4,623.1	₹174402 Cr	82.11	14.04	106.21	₹2163 Cr
2,297	₹126811 Cr	94.64	8.17	33.94	₹889 Cr
1,241.6	₹123685 Cr	27.41	9.42	62.53	₹5040 Cr
1,355.9	₹111868 Cr	39.95	11.08	59.2	₹4196 Cr
1,383.7	₹111650 Cr	38.54	10.86	52.6	₹3879 Cr
2,470.7	₹102196 Cr	45.57	17.23	76.26	₹1913 Cr
1,684	₹96951 Cr	26.11	17.95	96.84	₹3505 Cr
2,010.6	₹91301 Cr	16.51	30.95	154.35	₹5333 Cr
3,140.9	₹50598 Cr	44.83	19.21	94.7	₹1027 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Mar 2020
₹1800 Cr	₹1743 Cr	₹1695 Cr	₹1487 Cr	₹1506 Cr	₹1425 Cr	₹1384 Cr	₹1406 Cr	₹1402 Cr	₹1537 Cr	₹1545 Cr	₹1373 Cr	₹1209 Cr	₹785 Cr	₹938 Cr	₹1044 Cr	₹857 Cr	₹1103 Cr	₹1063 Cr	₹1080 Cr	₹1154 Cr	₹888 Cr	₹859 Cr	₹832 Cr	₹884 Cr	₹635 Cr
₹61 Cr	₹111 Cr	₹63 Cr	₹84 Cr	₹58 Cr	₹44 Cr	₹58 Cr	₹60 Cr	₹51 Cr	₹42 Cr	₹37 Cr	₹53 Cr	₹38 Cr	₹39 Cr	₹62 Cr	₹66 Cr	₹74 Cr	₹65 Cr	₹46 Cr	₹51 Cr	₹62 Cr	₹47 Cr	₹35 Cr	₹20 Cr	₹32 Cr	₹46 Cr
₹1862 Cr	₹1854 Cr	₹1759 Cr	₹1571 Cr	₹1563 Cr	₹1469 Cr	₹1443 Cr	₹1465 Cr	₹1453 Cr	₹1580 Cr	₹1583 Cr	₹1427 Cr	₹1246 Cr	₹824 Cr	₹1000 Cr	₹1110 Cr	₹931 Cr	₹1168 Cr	₹1109 Cr	₹1132 Cr	₹1216 Cr	₹935 Cr	₹895 Cr	₹852 Cr	₹916 Cr	₹681 Cr
₹1422 Cr	₹1338 Cr	₹1368 Cr	₹1279 Cr	₹1239 Cr	₹1173 Cr	₹1120 Cr	₹1203 Cr	₹1229 Cr	₹1271 Cr	₹1294 Cr	₹1131 Cr	₹980 Cr	₹654 Cr	₹686 Cr	₹784 Cr	₹622 Cr	₹786 Cr	₹742 Cr	₹730 Cr	₹743 Cr	₹585 Cr	₹620 Cr	₹558 Cr	₹496 Cr	₹419 Cr
₹551 Cr	₹624 Cr	₹498 Cr	₹398 Cr	₹425 Cr	₹392 Cr	₹418 Cr	₹357 Cr	₹316 Cr	₹401 Cr	₹394 Cr	₹377 Cr	₹331 Cr	₹207 Cr	₹351 Cr	₹362 Cr	₹344 Cr	₹414 Cr	₹395 Cr	₹428 Cr	₹498 Cr	₹375 Cr	₹299 Cr	₹318 Cr	₹445 Cr	₹286 Cr
₹4 Cr	₹10 Cr	₹4 Cr	₹8 Cr	₹11 Cr	₹7 Cr	₹23 Cr	₹6 Cr	₹6 Cr	₹10 Cr	₹5 Cr	₹6 Cr	₹5 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹90 L	₹2 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹76 L	₹47 L	₹47 L
₹435 Cr	₹506 Cr	₹362 Cr	₹284 Cr	₹313 Cr	₹288 Cr	₹299 Cr	₹257 Cr	₹218 Cr	₹298 Cr	₹283 Cr	₹290 Cr	₹261 Cr	₹111 Cr	₹311 Cr	₹324 Cr	₹308 Cr	₹380 Cr	₹366 Cr	₹401 Cr	₹472 Cr	₹349 Cr	₹273 Cr	₹293 Cr	₹420 Cr	₹262 Cr
₹317 Cr	₹367 Cr	₹261 Cr	₹184 Cr	₹215 Cr	₹187 Cr	₹205 Cr	₹164 Cr	₹144 Cr	₹192 Cr	₹192 Cr	₹194 Cr	₹194 Cr	₹79 Cr	₹232 Cr	₹241 Cr	₹229 Cr	₹286 Cr	₹273 Cr	₹302 Cr	₹351 Cr	₹260 Cr	₹204 Cr	₹219 Cr	₹314 Cr	₹195 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
—	—	—	—	—	—	—
₹16 Cr	₹16 Cr	₹16 Cr	₹16 Cr	₹16 Cr	₹16 Cr	₹15 Cr
₹46 Cr	₹5 L	₹1 Cr	₹2 Cr	₹13 Cr	₹25 Cr	₹16 Cr
₹10296 Cr	₹9134 Cr	₹8706 Cr	₹7941 Cr	₹7128 Cr	₹5861 Cr	₹3614 Cr
₹10296 Cr	₹9134 Cr	₹8706 Cr	₹7941 Cr	₹7128 Cr	₹5861 Cr	₹3614 Cr
₹10358 Cr	₹9151 Cr	₹8724 Cr	₹7959 Cr	₹7158 Cr	₹5903 Cr	₹3646 Cr
₹70 Cr	₹78 Cr	₹107 Cr	₹3 Cr	₹4 Cr	₹4 Cr	₹4 Cr
₹152 Cr	₹163 Cr	₹170 Cr	₹84 Cr	₹88 Cr	₹74 Cr	₹74 Cr
₹65 Cr	₹71 Cr	₹75 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr
₹196 Cr	₹146 Cr	₹137 Cr	₹0	₹0	₹0	₹0
₹482 Cr	₹457 Cr	₹489 Cr	₹90 Cr	₹94 Cr	₹80 Cr	₹81 Cr
—	—	—	—	—	—	—
₹834 Cr	₹820 Cr	₹768 Cr	₹587 Cr	₹463 Cr	₹396 Cr	₹249 Cr
₹658 Cr	₹620 Cr	₹520 Cr	₹109 Cr	₹76 Cr	₹62 Cr	₹82 Cr
₹117 Cr	₹125 Cr	₹111 Cr	₹32 Cr	₹43 Cr	₹54 Cr	₹28 Cr
₹1608 Cr	₹1565 Cr	₹1398 Cr	₹729 Cr	₹582 Cr	₹513 Cr	₹359 Cr
₹12449 Cr	₹11173 Cr	₹10611 Cr	₹8778 Cr	₹7834 Cr	₹6496 Cr	₹4086 Cr
₹10 Cr	₹21 Cr	₹16 Cr	₹22 Cr	₹13 Cr	₹75 Cr	₹12 Cr
₹243 Cr	₹269 Cr	₹320 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹5 Cr
—	—	—	—	—	—	—
₹6785 Cr	₹5613 Cr	₹5012 Cr	₹2295 Cr	₹2081 Cr	₹1431 Cr	₹1348 Cr
₹2292 Cr	₹1466 Cr	₹1065 Cr	₹724 Cr	₹579 Cr	₹476 Cr	₹380 Cr
₹4492 Cr	₹4147 Cr	₹3947 Cr	₹1571 Cr	₹1502 Cr	₹954 Cr	₹968 Cr
₹342 Cr	₹151 Cr	₹238 Cr	₹177 Cr	₹181 Cr	₹338 Cr	₹188 Cr
₹83 Cr	₹88 Cr	₹119 Cr	₹129 Cr	₹286 Cr	₹78 Cr	₹82 Cr
₹4 Cr	₹4 Cr	₹662 Cr	₹0	₹2 Cr	₹2 Cr	₹2 Cr
₹4922 Cr	₹4390 Cr	₹4966 Cr	₹1877 Cr	₹1982 Cr	₹1372 Cr	₹1240 Cr
—	—	—	—	—	—	—
₹0	₹0	₹0	₹0	₹155 Cr	₹0	₹0
₹1744 Cr	₹1685 Cr	₹1655 Cr	₹1945 Cr	₹1186 Cr	₹1275 Cr	₹756 Cr
₹1891 Cr	₹1517 Cr	₹1559 Cr	₹871 Cr	₹1075 Cr	₹671 Cr	₹602 Cr
₹3359 Cr	₹2556 Cr	₹1839 Cr	₹3771 Cr	₹3093 Cr	₹3006 Cr	₹1325 Cr
₹128 Cr	₹150 Cr	₹103 Cr	₹91 Cr	₹97 Cr	₹84 Cr	₹71 Cr
₹404 Cr	₹875 Cr	₹489 Cr	₹222 Cr	₹247 Cr	₹88 Cr	₹92 Cr
₹7527 Cr	₹6783 Cr	₹5645 Cr	₹6901 Cr	₹5852 Cr	₹5124 Cr	₹2846 Cr
₹5918 Cr	₹5218 Cr	₹4247 Cr	₹6172 Cr	₹5270 Cr	₹4611 Cr	₹2487 Cr
₹12449 Cr	₹11173 Cr	₹10611 Cr	₹8778 Cr	₹7834 Cr	₹6496 Cr	₹4086 Cr
₹626	₹555	₹530	₹483	₹435	₹359	₹234
₹626	₹555	₹530	₹483	₹435	₹359	₹234

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
₹1465 Cr	₹1063 Cr	₹1133 Cr	₹1055 Cr	₹1619 Cr	₹1335 Cr	₹993 Cr
₹277 Cr	₹212 Cr	₹224 Cr	₹38 Cr	-₹28 Cr	₹17 Cr	₹32 Cr
-₹254 Cr	-₹6 Cr	-₹53 Cr	-₹418 Cr	-₹393 Cr	-₹436 Cr	-₹80 Cr
₹1487 Cr	₹1269 Cr	₹1303 Cr	₹675 Cr	₹1197 Cr	₹916 Cr	₹945 Cr
₹1031 Cr	₹915 Cr	₹997 Cr	₹364 Cr	₹791 Cr	₹605 Cr	₹701 Cr
₹138 Cr	₹1705 Cr	-₹1757 Cr	₹1208 Cr	-₹1003 Cr	-₹1524 Cr	-₹766 Cr
-₹417 Cr	-₹433 Cr	-₹799 Cr	₹15 Cr	₹35 Cr	₹1238 Cr	-₹7 Cr
₹752 Cr	₹2186 Cr	-₹1560 Cr	₹1587 Cr	-₹177 Cr	₹319 Cr	-₹72 Cr
₹2556 Cr	₹357 Cr	₹1909 Cr	₹319 Cr	₹492 Cr	₹169 Cr	₹236 Cr
₹51 Cr	₹13 Cr	₹8 Cr	₹3 Cr	₹3 Cr	₹4 Cr	₹5 Cr
₹3359 Cr	₹2556 Cr	₹357 Cr	₹1909 Cr	₹319 Cr	₹492 Cr	₹169 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Gland Pharma Share Price

3158.90+92.30 (+3.01%)

+63.77% past 1 Year

Shareholding summary

Promoters

45.75%

FII

10.36%

DII

3.69%

29.52%

Others

10.68%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
45.75%	51.77%	51.83%	51.83%	51.83%	51.83%
10.36%	8.74%	7.29%	7.58%	7.90%	7.39%
3.69%	2.21%	1.58%	1.57%	2.44%	2.19%
29.52%	28.23%	31.78%	31.42%	30.19%	30.67%
10.68%	9.05%	7.52%	7.60%	7.64%	7.92%

Bulk & block deals

Name

Bofa Securities Europe Sa

North Rock Sg Vcc

Fosun Pharma Industrial Pte. Ltd.

Icici Prudential Mutual Fund

Axis Mutual Fund

Kotak Mahindra Mutual Fund

Aditya Birla Sun Life Mutual Fund

Sbi Life Insurance Company Limited

Hdfc Standard Life Insurance Co Ltd

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
17 Sep 2026	Purchase	42.40 Cr	₹2,826.60	1.50 L	Block	0.090903	NSE
17 Sep 2026	Sell	42.40 Cr	₹2,826.60	1.50 L	Block	0.090903	NSE
04 Sep 2026	Sell	649.29 Cr	₹2,833.45	22.91 L	Bulk	1.389068	BSE
04 Sep 2026	Sell	2,150.36 Cr	₹2,827.38	76.06 L	Bulk	4.610324	BSE
04 Sep 2026	Purchase	293.68 Cr	₹2,826.60	10.39 L	Bulk	0.629824	BSE
04 Sep 2026	Purchase	383.57 Cr	₹2,826.60	13.57 L	Bulk	0.82259	BSE
04 Sep 2026	Purchase	789.47 Cr	₹2,826.60	27.93 L	Bulk	1.693069	BSE
04 Sep 2026	Purchase	25.44 Cr	₹2,826.60	90 K	Block	0.054556	BSE
04 Sep 2026	Purchase	118.72 Cr	₹2,826.60	4.20 L	Block	0.254597	BSE
04 Sep 2026	Purchase	153.06 Cr	₹2,826.60	5.42 L	Block	0.328248	BSE

Insider trading & SAST

Client name

Mirae Asset Mutual Fund

Jayatheerth Advani

K Raghuramachandra Rao

Jayatheerth Advani

Sreenivasa Rao Suragam

Jayatheerth Advani

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
03 Aug 2026	Other	Disposal	0.18	4.98	0	—	3.01 L	13 Jul 2026	Market	82,10,838	SAST	29(2)	—
04 Jun 2026	Designated Person	Disposal	0.000606	0	23.55 L	₹2,355	1 K	01 Jun 2026	Market Sale	1,082	Insider Trading	—	Equity Shares
28 May 2026	Designated Person	Disposal	0.000607	0	23.46 L	₹2,345.90	1 K	25 May 2026	Market Sale	1,044	Insider Trading	—	Equity Shares
28 May 2026	Designated Person	Disposal	0.000607	0	23.20 L	₹2,319.70	1 K	27 May 2026	Market Sale	44	Insider Trading	—	Equity Shares
25 May 2026	Designated Person	Disposal	0.000303	0	11.78 L	₹2,355	500	21 May 2026	Market Sale	2,082	Insider Trading	—	Equity Shares
25 May 2026	Designated Person	Disposal	0.000303	0	11.50 L	₹2,300	500	21 May 2026	Market Sale	1,350	Insider Trading	—	Equity Shares
21 May 2026	Designated Person	Disposal	0.000607	0	21.70 L	₹2,170	1 K	18 May 2026	Market Sale	1,850	Insider Trading	—	Equity Shares
21 May 2026	Designated Person	Disposal	0.000607	0	22.35 L	₹2,235	1 K	19 May 2026	Market Sale	2,582	Insider Trading	—	Equity Shares
21 May 2026	Designated Person	Disposal	0.00021	0	7.74 L	₹2,238	346	19 May 2026	Market Sale	3,582	Insider Trading	—	Equity Shares
11 Feb 2026	Designated Person	Disposal	0.000061	0	1.89 L	₹1,888	100	09 Feb 2026	Market Sale	3,928	Insider Trading	—	Equity Shares

Gland Pharma Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Gland Pharma Share Price

Gland Pharma Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Gland Pharma Share Price

Gland Pharma Share Price

Oscillators

Moving averages

Gland Pharma Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Gland Pharma Share Price

Corporate Actions

Company details

Gland Pharma Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Gland Pharma Share Price

News

Gland Pharma Receives USFDA Approval For Methylprednisolone Injectable Suspension

Gland Pharma Reports Rs 28.31 Crores BSE Block Trade

Gland Pharma Reports Rs 18.16 Crores BSE Block Trade

Gland Pharma Reports Rs 37.23 Crores BSE Block Trade At Rs 3038

Gland Pharma Reports Rs 71.91 Crores BSE Block Trade

Nomura Maintains Buy View on Gland Pharma With Higher Target Price

Gland Pharma Approves Investment To Acquire Majority Stake In Novelstar Pharma

Gland Pharma Reports Rs 29.27 Crores BSE Block Trade

Gland Pharma to hold analyst and investor meetings on September 11

Gland Pharma sees Rs 2,178 crore block trade in pre open session

Gland Pharma faces potential 5 percent promoter stake sale via block deal

Gland Pharma gets USFDA clearance at VSEZ sterile oncology facility inspection

Gland Pharma schedules investor and analyst meetings in early September 2026

Goldman Sachs maintains sell on Gland Pharma, cites expensive valuation

Jefferies upgrades Gland Pharma to Buy after Q1 FY27 beat

Gland Pharma posts higher Q1 EBITDA and margin on yearly basis

Gland Pharma Q1 revenue rises to Rs 1,800 crores from Rs 1,500 crores

Gland Pharma reports higher first quarter net profit on yearly basis

Gland Pharma forms CDMO partnership for sterile injectable production

Gland Pharma partners Neuland Laboratories to expand sterile API capabilities

Gland Pharma Ltd Share Price Today

Gland Pharma Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator